Therapeutics News

After receiving a warning letter from the FDA, the online retailer Amazon removed seven unregulated eye drop products from its website.

The recent FDA warning about 26 potentially contaminated eye drop products, including some marketed under CVS Health, Leader, Rugby, Rite Aid, Target Up&Up and Velocity Pharma, may have caused some confusion among consumers.

Epion Therapeutics has initiated its phase 3 Apricity trials for EpiSmart, a minimally invasive drug-device combination indicated for epithelium-on cross-linking in the treatment of keratoconus.

Dry eye disease is chronic, multifactorial and complex. As a result, management plans have to account for many variables, from underlying conditions to work environments.

NEW ORLEANS — New research in dry eye disease suggests the next few years will bring significant advancements in treatment for patients, according to a speaker at Academy ’23.

The complement component 5 inhibitor avacincaptad pegol may have potential as a treatment to reduce geographic atrophy lesion growth and slow progression of disease, according to a study published in The Lancet.

Calcium channel blocker use was associated with an average 39% higher odds of glaucoma, as well as thinner inner retinal thickness, in a cross-sectional study of UK Biobank data.

LAS VEGAS — Visus Therapeutics completed one clinical trial for Brimochol PF, a once-daily drop for presbyopia, earlier this year and is currently enrolling patients for a second trial, a company executive said at Vision Expo West.

LAS VEGAS — The recent FDA approval of Ryzumvi for the reversal of drug-induced mydriasis has created the opportunity to perform more dilated, comprehensive eye exams, according to Paul M. Karpecki, OD, FAAO.

OKYO Pharma has completed patient enrollment for the randomized portion of its phase 2 clinical trial of OK-101, a topical treatment for dry eye disease, the company announced in a press release.